NASDAQ$UPB
Upstream Bio Inc · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
Upstream Bio reported Q1 2025, revenue of $85M, net income of $14M, diluted EPS of $0.35.
For Q1 2025, Upstream Bio reported revenue of $85M, net income of $14M, diluted EPS was $0.35. The filing highlights segment performance, liquidity, and management commentary on the period.
- Revenue $85M.
- Net income $14M.
- Diluted EPS $0.35.
Headline financials
Revenue & EPS history
Upstream Bio Inc · Revenue · Quarterly
$566K
Forward guidance
Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.
Tailwinds
- Headline results and segment trends anchor the quarter.
- Liquidity and balance-sheet capacity support operations.
- Strategic initiatives outlined in MD&A.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items affect year-over-year comparability.
- Execution risk on growth or restructuring plans.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports · overlaid with Q1 2025
+0.8%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+4.5%
Avg return
30 days after
67%
4 / 6 earnings
Positive
+7.9%
Q2 2025
Best reaction
-5.4%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.5% | -8.4% | — | |
| Q1 2026 | +4.7% | -5.3% | -31.9% | |
| Q3 2025 | -4.3% | -6.2% | +10.8% | |
| Q2 2025 | +7.9% | +7.0% | +28.8% | |
| Q1 2025 | -5.4% | +1.6% | +24.8% | |
| Q3 2024 | +1.7% | -0.7% | -10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro